An American musician who has lived in Russia for more than a decade has been arrested on suspicion of drug trafficking, Russian news media reported Saturday.
The reports said Michael Travis Leake is suspected of selling mephedrone, whose effects are similar to those of cocaine and MDMA.
A Moscow court ordered him to be held for two months in pre-trial detention, the reports said.
He faces charges of production or distribution of drugs, which carry a sentence of up to 20 years in prison.
An Instagram page under the name Travis Leake Instagram identifies him as the singer for the band Lovi Noch (Seize the Night).
News reports said Leake is a former paratrooper with the US military and has lived in Moscow since 2010.
Russian drug laws are strict.
WNBA star Brittney Griner was arrested in February 2022 after vape canisters containing cannabis oil were found in her luggage at a Moscow airport.
She was sentenced to nine years in prison, but was released in December in an exchange for US-imprisoned Russian arms dealer Viktor Bout.
The US State Department said in an emailed statement to The Associated Press that it was aware of the reports that a US citizen had recently been arrested in Moscow.
It said when a US citizen is detained overseas, the department “pursues consular access as soon as possible and works to provide all appropriate consular assistance.”
The department said it would have no further comment due to privacy considerations.
The post US musician, ex-paratrooper Michael Travis Leake arrested in Moscow on drug trafficking charges appeared first on REPORT DOOR.laws mdma
Law & Regulation3 days ago
Psilocybin study for bipolar depression encourages more research
LSD4 days ago
TECH HEAVY: The Magnificent Seven has suddenly become the Fantastic Four
Psilocybin3 days ago
Magic Mushroom Edibles: Everything to Know, from Chocolates to Drops
Ketamine3 days ago
Prepping the psychedelic industry for MDMA approval
Psychedelics3 days ago
Psychedelics Effects on Sexual Functions
Law & Regulation2 days ago
Enveric sells cannabis patents to focus on psilocin candidates